<code id='FD55E1154C'></code><style id='FD55E1154C'></style>
    • <acronym id='FD55E1154C'></acronym>
      <center id='FD55E1154C'><center id='FD55E1154C'><tfoot id='FD55E1154C'></tfoot></center><abbr id='FD55E1154C'><dir id='FD55E1154C'><tfoot id='FD55E1154C'></tfoot><noframes id='FD55E1154C'>

    • <optgroup id='FD55E1154C'><strike id='FD55E1154C'><sup id='FD55E1154C'></sup></strike><code id='FD55E1154C'></code></optgroup>
        1. <b id='FD55E1154C'><label id='FD55E1154C'><select id='FD55E1154C'><dt id='FD55E1154C'><span id='FD55E1154C'></span></dt></select></label></b><u id='FD55E1154C'></u>
          <i id='FD55E1154C'><strike id='FD55E1154C'><tt id='FD55E1154C'><pre id='FD55E1154C'></pre></tt></strike></i>

          entertainment

          entertainment

          author:focus    Page View:25
          Andrew Trister, an oncologist and veteran of big technology companies and research, is Verily's new chief scientific officer.

          As Verily aims to get on track, the Alphabet life science company has hired Andrew Trister, an oncologist and veteran of big technology companies and research, as its new chief scientific officer.

          Trister will lead Verily’s population health initiatives, including public health solutions like the company’s ongoing work to combat disease-carrying mosquito populations and a program that helps wastewater treatment plants monitor for pathogens. He will also consult across Verily’s diverse projects.

          advertisement

          Trister’s focus on public health will build on his recent role as a deputy director at the Bill and Melinda Gates Foundation, where he led digital health, including a project to build tech infrastructure to help with malaria testing. Trister also led the foundation’s Covid-19 response. In 2016, he was an early health hire at Apple. There, he worked on programs like a heart health study with Janssen, an app to promote healthy habits with Aetna, and research into digital biomarkers for Alzheimer’s disease with Eli Lilly and Evidation.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          I was wrong about Geron's blood cancer drug. Now, is it a takeover target?
          I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

          MollyFerguson/STATIwaswrongaboutGeron.Foryears,I’vebelieved—anddeclaredpublicly—thatGeron’sefforttod

          read more
          Hollywood unions extend contract negotiations for actors
          Hollywood unions extend contract negotiations for actors

          1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

          read more

          FDA gives detailed accounting of AI

          AdobeTheFoodandDrugAdministrationonThursdayreleasedanewaccountingofartificialintelligencetoolscleare